Valuation: Zai Lab Limited

Market Cap 2.05B 16.1B 1.78B 1.66B 1.52B 2.88B 196B 2.92B 19.58B 7.68B 97.55B 7.71B 7.54B 327B P/E 2026 *
-8.14x
P/E 2027 * -9.72x
Enterprise Value 1.56B 12.23B 1.36B 1.26B 1.16B 2.19B 149B 2.22B 14.87B 5.84B 74.1B 5.86B 5.73B 248B EV / Sales 2026 *
3.48x
EV / Sales 2027 * 2.83x
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
1 day+0.78%
1 week-7.02%
1 month-1.11%
3 months-13.18%
6 months+8.91%
Current year+4.76%
1 week 14.07
Extreme 14.07
15.1
1 month 14.07
Extreme 14.07
16.5
Current year 12.31
Extreme 12.31
20.42
1 year 12.31
Extreme 12.31
31.4
3 years 10.56
Extreme 10.56
35.5
5 years 10.56
Extreme 10.56
119.5
10 years 10.56
Extreme 10.56
151.2
Manager TitleAgeSince
Chief Executive Officer 61 01/04/2014
Director of Finance/CFO 58 07/07/2023
President 62 01/12/2022
Director TitleAgeSince
Chairman 61 01/04/2014
Director/Board Member 83 01/01/2017
Director/Board Member 75 01/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
+0.78%-7.02% - - 2.05B
+3.29%+16.25%+39.81%+2.79% 76.15B
-2.75%+48.50%+48.50%+48.50% 47.83B
+2.72%-9.39%+17.04%+176.83% 48.89B
-3.81%+7.74%-54.57%-54.17% 41.37B
-2.40%+0.38%+58.55%-24.89% 29.99B
-2.82%+1.57%+59.59%+87.57% 24.23B
-5.35%+1.39%+85.45%-53.41% 21.75B
-1.59%-3.61%-11.53%+150.58% 19.25B
-0.42%+2.89%+74.55%+128.45% 17.14B
Average -1.61%+1.48%+35.27%+51.36% 36.29B
Weighted average by Cap. -1.48%+2.98%+30.74%+43.63%

Financials

2026 *2027 *
Net sales 448M 3.51B 389M 362M 333M 628M 42.73B 638M 4.27B 1.68B 21.27B 1.68B 1.64B 71.33B 595M 4.66B 517M 481M 442M 834M 56.76B 847M 5.67B 2.23B 28.26B 2.23B 2.18B 94.75B
Net income -244M -1.91B -212M -198M -181M -343M -23.31B -348M -2.33B -914M -11.6B -917M -897M -38.91B -159M -1.25B -138M -129M -118M -223M -15.16B -226M -1.52B -595M -7.55B -597M -583M -25.31B
Net Debt -493M -3.87B -429M -399M -367M -692M -47.11B -703M -4.71B -1.85B -23.45B -1.85B -1.81B -78.64B -371M -2.91B -323M -300M -276M -521M -35.45B -529M -3.54B -1.39B -17.65B -1.39B -1.36B -59.18B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
1,784
Date Price Change Volume
31/07/26 HK$14.30 +0.78% 4,088,453
30/07/26 HK$14.19 -1.46% 3,315,700
29/07/26 HK$14.40 -3.68% 4,970,105
28/07/26 HK$14.95 +0.54% 4,274,612
27/07/26 HK$14.87 -3.32% 5,385,415
Trader
Investor
-
Global
-
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
18.27USD
Average target price
33.30USD
Spread / Average Target
+82.28%

Quarterly revenue - Rate of surprise